These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 13497364)
1. Lysergic acid diethylamide (LSD-25) antagonists. II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-methyl-d-lysergic acid diethylamide). ABRAMSON HA; SKLAROFSKY B; BARON MO; FREMONT-SMITH N AMA Arch Neurol Psychiatry; 1958 Feb; 79(2):201-7. PubMed ID: 13497364 [No Abstract] [Full Text] [Related]
2. Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei. Larson AA; Chinn C; Proudfit HK; Anderson EG J Pharmacol Exp Ther; 1981 Apr; 217(1):99-104. PubMed ID: 6110778 [TBL] [Abstract][Full Text] [Related]
3. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats. Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504 [TBL] [Abstract][Full Text] [Related]
4. Cross tolerance between D-2-brom-lysergic acid diethylamide (BOL-148) and the D-diethylamide of lysergic acid (LSD-25). ISBELL H; MINER EJ; LOGAN CR Psychopharmacologia; 1959 Nov; 1():109-16. PubMed ID: 14405871 [No Abstract] [Full Text] [Related]
5. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide. Burris KD; Sanders-Bush E Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans. Dolder PC; Schmid Y; Haschke M; Rentsch KM; Liechti ME Int J Neuropsychopharmacol; 2015 Jun; 19(1):. PubMed ID: 26108222 [TBL] [Abstract][Full Text] [Related]
7. Lysergic acid diethylamide (LSD-25). XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. ABRAMSON HA J Ment Sci; 1960 Jul; 106():1120-3. PubMed ID: 13681136 [No Abstract] [Full Text] [Related]
8. [Effects of D-lysergic acid diethylamide (LSD-25) and 2-bromo-D-lysergic acid diethylamide (BOL-148) on sleeping behavior in rats]. Loew DM; Depoortere H; Vigouret JM Naunyn Schmiedebergs Arch Pharmakol; 1970; 266(4):394-5. PubMed ID: 4326420 [No Abstract] [Full Text] [Related]
9. [Psychopathological experiences with the combined action of lysergic acid mono- & diethylamide (LAE-32, LSD-25)]. CALLIERI B; RAVETTA M Riv Sper Freniatr Med Leg Alien Ment; 1957 Jul; 81(2):267-313. PubMed ID: 13466954 [No Abstract] [Full Text] [Related]
10. Use of a new compound, UML-491 (1-methyl-D-lysergic acid butanolamide), in the prevention of various types of headache. GRAHAM JR N Engl J Med; 1960 Dec; 263():1273-7. PubMed ID: 13707731 [No Abstract] [Full Text] [Related]
11. [Effect of monoethylamide (LAE) and diethylamide (LSD) of lysergic acid on behavior of mouse with imino-beta, beta-dipropionitrile induced circular movement]. WIDLOCHER D; NAKAJIMA H; THUILLIER J C R Seances Soc Biol Fil; 1957; 151(4):668-70. PubMed ID: 13489946 [No Abstract] [Full Text] [Related]
12. Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25). ISBELL H; MINER EJ; LOGAN CR Psychopharmacologia; 1959; 1():20-8. PubMed ID: 14405872 [No Abstract] [Full Text] [Related]
13. Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial. Dolder PC; Liechti ME; Rentsch KM J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28548305 [TBL] [Abstract][Full Text] [Related]
14. Automated extraction of lysergic acid diethylamide (LSD) and N-demethyl-LSD from blood, serum, plasma, and urine samples using the Zymark RapidTrace with LC/MS/MS confirmation. de Kanel J; Vickery WE; Waldner B; Monahan RM; Diamond FX J Forensic Sci; 1998 May; 43(3):622-5. PubMed ID: 9608700 [TBL] [Abstract][Full Text] [Related]
15. [Effect of d-lysergic acid diethylamide and related compounds on melanophores]. BERDE B; CERLETTI A Helv Physiol Pharmacol Acta; 1956; 14(3):325-33. PubMed ID: 13405353 [No Abstract] [Full Text] [Related]
16. Antagonism of d-lysergic acid diethylamide and mescaline by 1-methyl-1, 2, 5, 6-tetrahydropyridine-N, N-diethyl-carboxamide (THPC). Dyer DC; Benington F; Morin RD Arch Int Pharmacodyn Ther; 1975 Oct; 217(2):197-200. PubMed ID: 127560 [TBL] [Abstract][Full Text] [Related]
17. Studies on lysergic acid diethylamide and related compounds. Part 8. Structural identification of new metabolites of lysergic acid diethylamide obtained by microbial transformation using Streptomyces roseochromogenes. Ishii H; Niwaguchi T; Nakahara Y; Hayashi M J Chem Soc Perkin 1; 1980; 4():902-5. PubMed ID: 7190156 [No Abstract] [Full Text] [Related]
18. Studies on the pharmacology of D-lysergic acid cycloalkylamides. VOTAVA Z; PODVALOVA I; SEMONSKY M Arch Int Pharmacodyn Ther; 1958 May; 115(1-2):114-30. PubMed ID: 13545891 [No Abstract] [Full Text] [Related]
19. New synthesis and characterization of (+)-lysergic acid diethylamide (LSD) derivatives and the development of a microparticle-based immunoassay for the detection of LSD and its metabolites. Li Z; Goc-Szkutnicka K; McNally AJ; Pilcher I; Polakowski S; Vitone S; Wu RS; Salamone SJ Bioconjug Chem; 1997; 8(6):896-905. PubMed ID: 9404664 [TBL] [Abstract][Full Text] [Related]
20. The pharmacology of mescaline and D-lysergic acid diethylamide (LSD). KOELLE GB N Engl J Med; 1958 Jan; 258(1):25-32. PubMed ID: 13493730 [No Abstract] [Full Text] [Related] [Next] [New Search]